Heidelberg, Germany

Christos Apostolidis

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2001-2021

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Christos Apostolidis: Innovator in Radiopharmaceuticals

Introduction

Christos Apostolidis is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of radiopharmaceuticals, holding a total of six patents. His work focuses on innovative methods for treating various cancers and utilizing radionuclides in medical applications.

Latest Patents

One of his latest patents is titled "Treatment of PMSA Expressing Cancers." This invention relates to a method for treating cancers that express PSMA, involving the administration of Ac-225-radiopharmaceuticals in effective dosages tailored to the patient's body weight. Another notable patent is "Radionuclides for Medical Use," which outlines methods for using Th-226 and its mother radionuclides in medicine. These radionuclides are particularly effective for therapeutic, diagnostic, prophylactic, and pain palliation purposes.

Career Highlights

Throughout his career, Christos has worked with the European Community, contributing to advancements in medical technology and treatment methodologies. His innovative approaches have garnered attention in the medical field, particularly in oncology.

Collaborations

Christos has collaborated with notable professionals in his field, including Roger Molinet and Willem Janssens. These partnerships have further enhanced his research and development efforts in radiopharmaceuticals.

Conclusion

Christos Apostolidis stands out as a key figure in the development of radiopharmaceuticals, with a focus on innovative cancer treatments. His contributions continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…